Clozapine Related Published Studies
Well-designed clinical trials related to Clozapine
Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. [2008.08]
A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. [2008.07]
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. [2008.05]
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. [2008.05]
Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.18]
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.11]
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. [2008.03.01]
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. [2008.02]
Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. [2008.01]
A Randomized Controlled Trial of the Cost-Utility of Second-Generation Antipsychotics in People with Psychosis and Eligible for Clozapine. [2007.12.18]
Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. [2007.10]
Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. [2007.10]
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. [2007.09]
The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. [2007.07]
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. [2007.02]
Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. [2007.01]
A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. [2006.12]
Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. [2006.11]
Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. [2006.10]
Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. [2006.09.15]
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. [2006.09.15]
Risperidone augmentation of clozapine : A critical review. [2006.09]
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. [2006.07]
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. [2006.05]
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. [2006.04]
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. [2006.04]
Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity. [2006.03]
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. [2006.02.02]
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. [2006.02]
Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity. [2005.11.19]
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. [2005.09.21]
Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. [2005.08]
Does clozapine decrease smoking? [2005.06]
The effects of clozapine and risperidone on spatial working memory in schizophrenia. [2005.05]
Steady-state bioequivalence study of clozapine tablet in schizophrenic patients. [2005.02.25]
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. [2005.02]
Plasma clozapine concentration coefficients of variation in a long-term study. [2005.01.01]
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. [2005.01]
Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. [2005.01]
Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. [2004.10]
Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. [2004.09]
Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. [2004.07]
Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. [2004.07]
The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. [2004.07]
Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. [2004.06]
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. [2004.05]
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. [2004.05]
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. [2004.04]
The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. [2004.03]
Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. [2004.02.10]
Do clozapine and risperidone affect social competence and problem solving? [2004.02]
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. [2004.01]
Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. [2004.01]
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. [2004.01]
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. [2004]
Weight gain with clozapine compared to first generation antipsychotic medications. [2004]
Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications. [2004]
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. [2003.09]
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. [2003.08]
Serum antimuscarinic activity during clozapine treatment. [2003.08]
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. [2003.08]
Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. [2003.06]
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. [2003.05]
Low blood selenium concentrations in schizophrenic patients on clozapine. [2003.03]
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. [2003.01.01]
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. [2003.01]
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). [2003.01]
Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. [2002.09]
Weight and blood pressure change during clozapine treatment. [2002.07]
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. [2002.06]
Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. [2002.04]
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. [2002.02]
Effects of haloperidol and clozapine on prepulse inhibition of the acoustic startle response and the N1/P2 auditory evoked potential in man. [2001.12]
Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. [2001.12]
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. [2001.11]
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. [2001.10]
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. [2001.10]
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. [2001.08]
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. [2001.01.01]
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. [2001.01]
Branded versus generic clozapine: bioavailability comparison and interchangeability issues. [2001]
Clinical effects of a randomized switch of patients from clozaril to generic clozapine. [2001]
Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. [2000.11]
Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. [2000.11]
Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. [2000.10]
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. [2000.09.26]
Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. [2000.09]
Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. [2000.08]
Clozapine and risperidone treatment of psychosis in Parkinson's disease. [2000.06]
Significant interaction between clozapine and cocaine in cocaine addicts. [2000.05.01]
Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. [2000.05]
Placebo-controlled trial of glycine added to clozapine in schizophrenia. [2000.05]
Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. [2000.01]
D-serine added to clozapine for the treatment of schizophrenia. [1999.11]
Double-blind study of clozapine dose response in chronic schizophrenia. [1999.11]
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. [1999.10]
Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. [1999.08]
Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. [1999.07.01]
Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. [1999.07]
Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. [1999.06]
A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. [1999.05.04]
|
